An announcement from Biohaven Ltd. ( (BHVN) ) is now available.
Biohaven Ltd. announced promising results from a pivotal study on troriluzole in treating Spinocerebellar Ataxia (SCA), showing a significant delay in disease progression by 50-70% compared to untreated patients. This translates to a 1.5-2.2 years delay over a 3-year period, with plans to submit a New Drug Application to the FDA in Q4 2024. The study, which is the largest clinical trial dataset in SCA, received positive feedback from the SCA community and healthcare professionals, highlighting the potential impact on patients’ quality of life.
For detailed information about BHVN stock, go to TipRanks’ Stock Analysis page.
